Our top pick for
Private investment firm P10 wrapped its initial public offering, selling 11.5 million shares at $12 each, below the expected price range of $14 to $16.Shares of PX will commence trading on the NYSE later today, but shares are available for limit orders on Robinhood and other platforms.
|Latest market close||$11.75|
|52-week range||$9.62 - $17.10|
|50-day moving average||$11.39|
|200-day moving average||$12.30|
|Wall St. target price||$14.40|
|Dividend yield||$0 (1.05%)|
|Earnings per share (TTM)||$0.13|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-30)||5.67%|
|1 month (2022-06-07)||1.73%|
|3 months (2022-04-07)||2.09%|
|6 months (2022-01-07)||-10.31%|
|1 year (2021-07-07)||60.08%|
|2 years (2020-07-07)||351.92%|
|3 years (2019-07-05)||693.92%|
|5 years (2017-07-07)||2,159.62%|
Valuing P10 stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of P10's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
P10's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 91x. In other words, P10 shares trade at around 91x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, P10's P/E ratio is best considered in relation to those of others within the asset management industry or those of similar companies.
P10's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $77.2 million.
The EBITDA is a measure of a P10's overall financial performance and is widely used to measure a its profitability.
To put P10's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||$161 million|
|Operating margin TTM||29.66%|
|Gross profit TTM||$150.5 million|
|Return on assets TTM||4.42%|
|Return on equity TTM||4.88%|
|Market capitalisation||$1.4 billion|
TTM: trailing 12 months
Dividend payout ratio: 6.98% of net profits
Recently P10 has paid out, on average, around 6.98% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.05% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), P10 shareholders could enjoy a 1.05% return on their shares, in the form of dividend payments. In P10's case, that would currently equate to about $0 per share.
While P10's payout ratio might seem low, this can signify that P10 is investing more in its future growth.
P10's most recent dividend payout was on 16 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 26 May 2022 (the "ex-dividend date").
P10's dividend payout ratio is perhaps best considered in relation to those of similar companies.
P10's shares were split on a 7:10 basis on 20 October 2021. So if you had owned 10 shares the day before before the split, the next day you'd have owned 7 shares. This wouldn't directly have changed the overall worth of your P10 shares – just the quantity. However, indirectly, the new 42.9% higher share price could have impacted the market appetite for P10 shares which in turn could have impacted P10's share price.
P10, Inc. , together with its subsidiaries, operates as a multi-asset class private market solutions provider in the alternative asset management industry in the United States. The company offers private equity, venture capital, private credit, impact investing, and private credit services, as well as primary fund of funds, secondary investment, and direct and co-investments services. It also provides tax credit transaction and consulting services. The company was founded in 1992 and is headquartered in Dallas, Texas. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.